April 10, 2017
Kyowa Hakko Kirin said on April 6 that burosumab (development code: KRN23), an investigational anti-FGF23 monoclonal IgG1 antibody, yielded favorable results in a global PII trial examining it for the treatment of pediatric patients with X-linked hypophosphatemia (XLH). The trial...read more